Trial reportFrontiers in cardiovascular medicine2026
Abnormal "
Trial report in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of epicardial adipose tissue (EAT) and gut microbiota (GM) in heart failure (HF) and atrial fibrillation (AF) have been extensively researched, but the role of them in individuals with concurrent HF with reduced ejection fraction (HFrEF) and AF (HFrEF_AF) is still unclear. Furthermore, the role of SGLT2i in HFrEF_AF patients is also not fully understood. The purpose of this study is to compare the differences in EAT and GM between HFrEF_AF and HFrEF patients without AF (HFrEF_NAF), and to analyse the relationship between them and the patients' heart structure, as well as the changes of them after SGLT2i treatment. Methods: 45 HFrEF_NAF patients and 39 HFrEF_AF patients were continuously recruited, with 26 patients from each group meeting the selection criteria. Fecal samples and CT scans were collected at baseline and after SGLT2i treatment for 3 months, respectively. The 16S rRNA gene of fecal samples was sequenced, and EAT volume (EATV) and EAT volume index (EATVI) values were measured and calculated with CT. These patients were followed up for up to 12 months to assess their long-term re-hospitalization rates. Results: The results showed that EATV [191.75 (119.59, 222.44) vs. 141.99 (97.10, 183.75)] and EATVI [105.07 (82.90, 116.39) mL/m Conclusion: EATV and EATVI in HFrEF_AF patients were significantly higher than in HFrEF_NAF patients. There may be an abnormal " Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=240632, ChiCTR2400088128.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.